New Vaccine Treatment for GNAS

Researchers from Oslo, Norway have released a new paper outlining the potential for use of a peptide vaccine to help patients with PMP exhibiting mutation in GNAS. They write:

Patients with GNAS-mutated pseudomyxoma peritonei (PMP) have a pre-existing immunity against mutated Gsa. Inhibition of anti-tumor T-cells by upregulation of immune checkpoint molecules results in insufficient immune response. The results suggest exporint peptide vaccination with Gsa peptides in combination with immune checkpoint inhibition as a possible curative treatment for PMP and other GNAS-mutated cancers.”



You can read this new paper here.